title: Early prediction of anthracycline cardiomyopathy using standard M-mode and digitized echocardiography.
abstract: In this study, we attempted to identify echocardiographic findings that can be used as early predictors of left ventricular dysfunction due to anthracyclines in 26 pediatric oncology patients. Retrospective review identified six patients (group 1 mean anthracycline dose = 337 +/- 123 mg/m2) who developed clinical evidence of cardiomyopathy and 20 consecutive patients followed prospectively (group 2 mean anthracycline dose = 298 +/- 102 mg/m2) who did not. All of the patients had serial m-mode echocardiography before and at approximately every 50 mg/m2 of anthracycline treatment depending on the dosage schedule. The following measurements were recorded: left ventricular dimensions and wall thickness, indices of left ventricular function, including systolic time intervals, shortening fraction, and ejection fraction. Using digitized echocardiography, the following parameters were recorded: peak and normalized systolic and diastolic velocities of the left ventricular chamber, posterior and septal wall velocities, and percent of posterior wall thickening. Variations from established normal longitudinal bounds and actual changes from pre-anthracycline values were compared for the two groups throughout the course of therapy. At 70 mg/m2 of anthracycline, group 1 showed significant deterioration in shortening fraction (mean change = 8.8 versus 2.5, p = .03), left ventricular velocity in diastole (2.9 versus 0.21, p = .04), left ventricular normalized velocity in systole (.65 versus 0.03, p = .02), and left ventricular normalized velocity in diastole (1.15 versus 0.002, p = .04) compared to group 2. These values were mostly compensated by 125 mg/m2, but they slowly deteriorated again at higher doses of anthracycline, leading to the appearance of clinical evidence of cardiomyopathy.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Division of Cardiology, U.B.C., Vancouver, Canada.
authors.forename: G G
authors.initials: GG
authors.lastname: Sandor
authors.forename: M
authors.initials: M
authors.lastname: Puterman
authors.forename: P
authors.initials: P
authors.lastname: Rogers
authors.forename: K W
authors.initials: KW
authors.lastname: Chan
authors.forename: S
authors.initials: S
authors.lastname: Pritchard
authors.forename: R
authors.initials: R
authors.lastname: Popov
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004317:Doxorubicin / Q000009:adverse effects*; D004452:Echocardiography / Q000379:methods*; D006333:Heart Failure / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis / Q000473:pathology; D006801:Humans; D007223:Infant; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D016277:Ventricular Function, Left
chemical_list: D004317:Doxorubicin